Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025

Emerging Treatment, Peptide Receptor Radionuclide Therapy, Provides New Treatment Option for Gastroenteropancreatic Neuroendocrine Tumours

With nuclear medicine therapeutics expected to represent
60% of the projected $26 billion global molecular nuclear
medicine market by 2030, new alternative treatments
are now beginning to emerge for conditions including
gastroenteropancreatic neuroendocrine tumours
(GEP-NETs). Of these nuclear medicine innovations, peptide
receptor radionuclide therapy (PRRT) is an option that
combines the advantages of two of the most successful
approaches to cancer treatment: external beam radiation
and tumour targeted therapy. This article by Stefano Buono
and Rachel Levine of Advanced Accelerator Applications
explores this treatment.

Scott Pharma – 25.03.2025
SMI – 24/03/2025
Chemspec Europe – 27.02.2025
PHARMAP: Mon 14 October 2024, 10.36
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
L.B. Bohle – 08.04.2025